Difference between revisions of "HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma"
| [unchecked revision] | [unchecked revision] |
| (2 intermediate revisions by the same user not shown) | |||
| Line 52: | Line 52: | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Signs and Symptoms''' | |'''Signs and Symptoms''' | ||
| − | | | + | |Diffusely distributed papules (common) |
| − | + | Localized papules (less common) | |
Ulcerated nodules, tumors, and plaques | Ulcerated nodules, tumors, and plaques | ||
| Line 77: | Line 77: | ||
==Morphologic Features== | ==Morphologic Features== | ||
| − | + | Pagetoid epithelial involvement (epidermal and adnexal) are typically observed, however the infiltrate may involve the entire dermis. <ref name=":2" /><ref>{{Cite journal|last=Saruta|first=Hiroshi|last2=Ohata|first2=Chika|last3=Muto|first3=Ikko|last4=Imamura|first4=Taichi|last5=Oku|first5=Eijiro|last6=Ohshima|first6=Koichi|last7=Nagafuji|first7=Koji|last8=Nakama|first8=Takekuni|date=2017-09|title=Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/28391645/|journal=The Journal of Dermatology|volume=44|issue=9|pages=1038–1042|doi=10.1111/1346-8138.13848|issn=1346-8138|pmid=28391645}}</ref> The dermal infiltrates range from monomorphic to pleomorphic. Rimming of subcutaneous fat spaces has been reported.Spongiosis can result in blister formation.<ref name=":4">{{Cite journal|last=Nofal|first=Ahmad|last2=Abdel-Mawla|first2=M. Yousry|last3=Assaf|first3=Magda|last4=Salah|first4=Eman|date=2012-10|title=Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation|url=https://pubmed.ncbi.nlm.nih.gov/22226429/|journal=Journal of the American Academy of Dermatology|volume=67|issue=4|pages=748–759|doi=10.1016/j.jaad.2011.07.043|issn=1097-6787|pmid=22226429}}</ref> | |
| + | |||
| + | The tumor cells typically consist of atypical small to large lymphocytes with indented nuclei, minimal cytoplasm, and occasional immunoblastic features. Histological signs of cytotoxicity are evident, including epidermal necrosis or ulceration, dermal necrosis, karyorrhexis, and rare angiocentric destruction.<ref name=":1" /><ref name=":2" /><ref name=":4" /> Ulceration can resemble pyoderma gangrenosum.<ref>{{Cite journal|last=Deenen|first=N. J.|last2=Koens|first2=L.|last3=Jaspars|first3=E. H.|last4=Vermeer|first4=M. H.|last5=Willemze|first5=R.|last6=de Rie|first6=M. A.|last7=Bekkenk|first7=M. W.|date=2019-02|title=Pitfalls in diagnosing primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/30259963/|journal=The British Journal of Dermatology|volume=180|issue=2|pages=411–412|doi=10.1111/bjd.17252|issn=1365-2133|pmid=30259963}}</ref> Notably, atypical CD8+ cytotoxic T cells exhibit pronounced pagetoid epidermotropism, particularly in cases with widespread lesions.<ref name=":0" /><ref>{{Cite journal|last=Willemze|first=Rein|last2=Jaffe|first2=Elaine S.|last3=Burg|first3=Günter|last4=Cerroni|first4=Lorenzo|last5=Berti|first5=Emilio|last6=Swerdlow|first6=Steven H.|last7=Ralfkiaer|first7=Elisabeth|last8=Chimenti|first8=Sergio|last9=Diaz-Perez|first9=José L.|date=2005-05-15|title=WHO-EORTC classification for cutaneous lymphomas|url=https://pubmed.ncbi.nlm.nih.gov/15692063/|journal=Blood|volume=105|issue=10|pages=3768–3785|doi=10.1182/blood-2004-09-3502|issn=0006-4971|pmid=15692063}}</ref> | ||
==Immunophenotype== | ==Immunophenotype== | ||
| − | |||
| − | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 87: | Line 87: | ||
!Finding!!Marker | !Finding!!Marker | ||
|- | |- | ||
| − | |Positive (universal)|| | + | |Positive (universal)||βF1+, TIA1+, granzyme B+, perforin+, CCR4+, CD45RA+, pSTAT3+, pSTAT5+, Ki-67+ |
|- | |- | ||
| − | |Positive (subset)|| | + | |Positive (subset)||CD8+ or CD8−/CD4− |
|- | |- | ||
| − | |Negative (universal)|| | + | |Negative (universal)||TCRγδ−, TCRδ− |
|- | |- | ||
| − | |Negative (subset)|| | + | |Negative (subset)||CD2− and/or CD5− <ref name=":2" /> |
|} | |} | ||
| + | Immunohistochemistry for phosphorylated STAT3 and STAT5 can be utilized to identify activation of the JAK/STAT pathway.<ref name=":5">{{Cite journal|last=Lee|first=Katie|last2=Evans|first2=Mark G.|last3=Yang|first3=Lei|last4=Ng|first4=Spencer|last5=Snowden|first5=Caroline|last6=Khodadoust|first6=Michael|last7=Brown|first7=Ryanne A.|last8=Trum|first8=Nicholas A.|last9=Querfeld|first9=Christiane|date=2021-12-09|title=Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway|url=https://pubmed.ncbi.nlm.nih.gov/34432866/|journal=Blood|volume=138|issue=23|pages=2435–2440|doi=10.1182/blood.2021012536|issn=1528-0020|pmc=8662071|pmid=34432866}}</ref><ref name=":6">{{Cite journal|last=Fanoni|first=Daniele|last2=Corti|first2=Laura|last3=Alberti-Violetti|first3=Silvia|last4=Tensen|first4=Cornelis P.|last5=Venegoni|first5=Luigia|last6=Vermeer|first6=Maarten|last7=Willemze|first7=Rein|last8=Berti|first8=Emilio|date=2018-12|title=Array-based CGH of primary cutaneous CD8+ aggressive EPIDERMO-tropic cytotoxic T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/30307677/|journal=Genes, Chromosomes & Cancer|volume=57|issue=12|pages=622–629|doi=10.1002/gcc.22673|issn=1098-2264|pmid=30307677}}</ref><ref name=":3" /> | ||
==Chromosomal Rearrangements (Gene Fusions)== | ==Chromosomal Rearrangements (Gene Fusions)== | ||
| − | + | In PCAETL, recurrent genomic events affecting genes involved in the cell cycle, chromatin regulation, and the JAK/STAT pathway have been reported, including complex genomic rearrangements and diverse JAK2 fusions.<ref name=":6" />Upregulated JAK-2 signaling is a consistent finding in nearly all cases, distinguishing PCAETL from other cytotoxic cutaneous T-cell lymphomas.Cases without JAK2 fusions often exhibit gain-of-function mutations in JAK2, STAT3, and STAT5B, alongside loss of negative regulators of the JAK/STAT pathway, particularly SH2B3.<ref name=":3" /> | |
| − | < | ||
| − | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 108: | Line 107: | ||
!Notes | !Notes | ||
|- | |- | ||
| − | |JAK2 fusions||KHDRBS1-JAK2, PCM1-JAK2, TFG-JAK2||Self-oligo/dimerization of JAK2|| | + | |JAK2 fusions||KHDRBS1-JAK2, PCM1-JAK2, TFG-JAK2||Self-oligo/dimerization of JAK2|| |
|Yes | |Yes | ||
|Unknown | |Unknown | ||
|Yes | |Yes | ||
| − | |Confer cytokine-independent survival ability, potential therapeutic target with JAK inhibitors.<ref name=":3">{{Cite journal|title=Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/33792220/|journal=Haematologica|date=2022-03-01|issn=1592-8721|pmc=8883537|pmid=33792220|pages=702–714|volume=107|issue=3|doi=10.3324/haematol.2020.274506|first=Armando N.|last=Bastidas Torres|first2=Davy|last2=Cats|first3=Jacoba J.|last3=Out-Luiting|first4=Daniele|last4=Fanoni|first5=Hailiang|last5=Mei|first6=Luigia|last6=Venegoni|first7=Rein|last7=Willemze|first8=Maarten H.|last8=Vermeer|first9=Emilio|last9=Berti}}</ref> | + | |Confer cytokine-independent survival ability, potential therapeutic target with JAK inhibitors.<ref name=":5" /><ref name=":6" /><ref name=":3">{{Cite journal|title=Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/33792220/|journal=Haematologica|date=2022-03-01|issn=1592-8721|pmc=8883537|pmid=33792220|pages=702–714|volume=107|issue=3|doi=10.3324/haematol.2020.274506|first=Armando N.|last=Bastidas Torres|first2=Davy|last2=Cats|first3=Jacoba J.|last3=Out-Luiting|first4=Daniele|last4=Fanoni|first5=Hailiang|last5=Mei|first6=Luigia|last6=Venegoni|first7=Rein|last7=Willemze|first8=Maarten H.|last8=Vermeer|first9=Emilio|last9=Berti}}</ref> |
|} | |} | ||
==Individual Region Genomic Gain / Loss / LOH== | ==Individual Region Genomic Gain / Loss / LOH== | ||
| − | |||
| − | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 143: | Line 140: | ||
|Unknown | |Unknown | ||
|No | |No | ||
| − | |Common in fusion-negative cases.<ref name=":3" /> | + | |Common in fusion-negative cases.<ref name=":5" /><ref name=":6" /><ref name=":3" /> |
|} | |} | ||
==Characteristic Chromosomal Patterns== | ==Characteristic Chromosomal Patterns== | ||
| − | |||
| − | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 161: | Line 156: | ||
|Unknown | |Unknown | ||
|Unknown | |Unknown | ||
| − | |Identified in fusion-negative cases.<ref name=":3" /> | + | |Identified in fusion-negative cases.<ref name=":5" /><ref name=":6" /><ref name=":3" /> |
|} | |} | ||
==Gene Mutations (SNV / INDEL)== | ==Gene Mutations (SNV / INDEL)== | ||
| Line 177: | Line 172: | ||
Fusion genes: KHDRBS1-JAK2, PCM1-JAK2, TFG-JAK2 | Fusion genes: KHDRBS1-JAK2, PCM1-JAK2, TFG-JAK2 | ||
|Self-oligo/dimerization | |Self-oligo/dimerization | ||
| − | | | + | | |
|MYC fusions | |MYC fusions | ||
|PTPRC, SH2B3 | |PTPRC, SH2B3 | ||
| Line 183: | Line 178: | ||
|Unknown | |Unknown | ||
|Yes | |Yes | ||
| − | |Potential therapeutic target with JAK inhibitors.<ref name=":3" /> | + | |Potential therapeutic target with JAK inhibitors.<ref name=":5" /><ref name=":6" /><ref name=":3" /> |
|} | |} | ||
| − | |||
| − | |||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||
| Line 213: | Line 206: | ||
==Additional Information== | ==Additional Information== | ||
| + | PCAETL has an aggressive progression, with a median survival time of 12 months. The prognosis is similar regardless of whether the morphology is small or large cell, or whether the lesions are localized or diffuse.<ref name=":1" /> | ||
==Links== | ==Links== | ||
Revision as of 20:30, 14 July 2024
Haematolymphoid Tumours (5th ed.)
 | This page is under construction |
(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)
Primary Author(s)*
Ahmed Eladely, MBBCh. Andrew Siref, MD.
Creighton University, Omaha, NE.
Cancer Category / Type
| Book | WHO Classification of Disease - Haematolymphoid Tumours (5th ed.) |
|---|---|
| Category | T-cell and NK-cell lymphoid proliferations and lymphomas |
| Family | Mature T-cell and NK-cell neoplasms |
| Type | Primary cutaneous T-cell lymphoid proliferations and lymphomas |
| Subtype | Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma |
Cancer Sub-Classification / Subtype
None
Definition / Description of Disease
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETL) is a rare and poorly characterized neoplastic proliferation of T lymphocytes with CD8 expression and cytotoxic molecules. PACETL is marked by epidermal necrosis, a high proliferation index, and aggressive clinical behavior. It should be distinguished from other rare epidermotropic subtypes of cutaneous gamma-delta T-cell lymphomas (such as gamma-delta mycosis fungoides), CD8+ mycosis fungoides, localized pagetoid reticulosis, type D lymphomatoid papulosis and Woringer-Kolopp disease.[1][2][3]
Synonyms / Terminology
Ketron–Goodman, disseminated pagetoid reticulosis, Berti lymphoma (Historical)
Epidemiology / Prevalence
PCAETL is rare, comprising less than 1% of all cutaneous T-cell lymphomas. It typically occurs in adults and shows a predilection for males.[1][3]
Clinical Features
| Signs and Symptoms | Diffusely distributed papules (common)
Localized papules (less common) Ulcerated nodules, tumors, and plaques Erosion or central necrosis Preceded by chronic, poorly defined patches (subset) Disseminate to visceral sites (lungs, testes, CNS) Lymph nodes spared |
| Laboratory Findings | None |
Sites of Involvement
PACETL can present with either localized or generalized skin lesions and may affect oral mucosa.[4]
Morphologic Features
Pagetoid epithelial involvement (epidermal and adnexal) are typically observed, however the infiltrate may involve the entire dermis. [3][5] The dermal infiltrates range from monomorphic to pleomorphic. Rimming of subcutaneous fat spaces has been reported.Spongiosis can result in blister formation.[6]
The tumor cells typically consist of atypical small to large lymphocytes with indented nuclei, minimal cytoplasm, and occasional immunoblastic features. Histological signs of cytotoxicity are evident, including epidermal necrosis or ulceration, dermal necrosis, karyorrhexis, and rare angiocentric destruction.[2][3][6] Ulceration can resemble pyoderma gangrenosum.[7] Notably, atypical CD8+ cytotoxic T cells exhibit pronounced pagetoid epidermotropism, particularly in cases with widespread lesions.[1][8]
Immunophenotype
| Finding | Marker |
|---|---|
| Positive (universal) | βF1+, TIA1+, granzyme B+, perforin+, CCR4+, CD45RA+, pSTAT3+, pSTAT5+, Ki-67+ |
| Positive (subset) | CD8+ or CD8−/CD4− |
| Negative (universal) | TCRγδ−, TCRδ− |
| Negative (subset) | CD2− and/or CD5− [3] |
Immunohistochemistry for phosphorylated STAT3 and STAT5 can be utilized to identify activation of the JAK/STAT pathway.[9][10][11]
Chromosomal Rearrangements (Gene Fusions)
In PCAETL, recurrent genomic events affecting genes involved in the cell cycle, chromatin regulation, and the JAK/STAT pathway have been reported, including complex genomic rearrangements and diverse JAK2 fusions.[10]Upregulated JAK-2 signaling is a consistent finding in nearly all cases, distinguishing PCAETL from other cytotoxic cutaneous T-cell lymphomas.Cases without JAK2 fusions often exhibit gain-of-function mutations in JAK2, STAT3, and STAT5B, alongside loss of negative regulators of the JAK/STAT pathway, particularly SH2B3.[11]
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| JAK2 fusions | KHDRBS1-JAK2, PCM1-JAK2, TFG-JAK2 | Self-oligo/dimerization of JAK2 | Yes | Unknown | Yes | Confer cytokine-independent survival ability, potential therapeutic target with JAK inhibitors.[9][10][11] |
Individual Region Genomic Gain / Loss / LOH
| Chr # | Gain / Loss / Amp / LOH | Minimal Region Genomic Coordinates [Genome Build] | Minimal Region Cytoband | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| 1p | Deletion | 1p | Yes | Unknown | No | Associated with chromatin remodeling and tumor suppression. | |
| 8p | Deletion | 8p | Yes | Unknown | No | Common in fusion-negative cases.[9][10][11] |
Characteristic Chromosomal Patterns
| Chromosomal Pattern | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|
| Deletions within 1p, 8p, 9q, 10p, 11q and 13q; gains within 7q, 8q, 17q and 21q | Yes | Unknown | Unknown | Identified in fusion-negative cases.[9][10][11] |
Gene Mutations (SNV / INDEL)
| Gene; Genetic Alteration | Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) | Prevalence (COSMIC / TCGA / Other) | Concomitant Mutations | Mutually Exclusive Mutations | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|---|
| JAK2
Fusion genes: KHDRBS1-JAK2, PCM1-JAK2, TFG-JAK2 |
Self-oligo/dimerization | MYC fusions | PTPRC, SH2B3 | Yes | Unknown | Yes | Potential therapeutic target with JAK inhibitors.[9][10][11] |
Epigenomic Alterations
Unknown
Genes and Main Pathways Involved
| Gene; Genetic Alteration | Pathway | Pathophysiologic Outcome |
|---|---|---|
| JAK2;Fusion with KHDRBS1, PCM1, TFG | JAK-STAT signaling | Upregulation leads to cytokine-independent activation. |
| SH2B3;Deletion | JAK-STAT negative regulation | Loss leads to hyperactivation of JAK2 signaling.[11] |
Genetic Diagnostic Testing Methods
JAK2 by Next-generation sequencing (NGS). SH2B3 by PCR or FISH.[11]
Familial Forms
Unknown
Additional Information
PCAETL has an aggressive progression, with a median survival time of 12 months. The prognosis is similar regardless of whether the morphology is small or large cell, or whether the lesions are localized or diffuse.[2]
Links
Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page (Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "http://www." portion.)
References
(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)
- ↑ 1.0 1.1 1.2 1.3 Berti, E.; et al. (1999-08). "Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior". The American Journal of Pathology. 155 (2): 483–492. doi:10.1016/S0002-9440(10)65144-9. ISSN 0002-9440. PMC 1866866. PMID 10433941. Check date values in:
|date=(help) - ↑ 2.0 2.1 2.2 2.3 Guitart, Joan; et al. (2017-05). "Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 30 (5): 761–772. doi:10.1038/modpathol.2016.240. ISSN 1530-0285. PMC 5413429. PMID 28128277. Check date values in:
|date=(help) - ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Robson, Alistair; et al. (2015-10). "Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop". Histopathology. 67 (4): 425–441. doi:10.1111/his.12371. ISSN 1365-2559. PMID 24438036. Check date values in:
|date=(help) - ↑ Travassos, Daphine Caxias; et al. (2022-06). "Primary cutaneous CD8+ cytotoxic T-cell lymphoma of the face with intraoral involvement, resulting in facial nerve palsy after chemotherapy". Journal of Cutaneous Pathology. 49 (6): 560–564. doi:10.1111/cup.14199. ISSN 1600-0560. PMID 35001425 Check
|pmid=value (help). Check date values in:|date=(help) - ↑ Saruta, Hiroshi; et al. (2017-09). "Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma". The Journal of Dermatology. 44 (9): 1038–1042. doi:10.1111/1346-8138.13848. ISSN 1346-8138. PMID 28391645. Check date values in:
|date=(help) - ↑ 6.0 6.1 Nofal, Ahmad; et al. (2012-10). "Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation". Journal of the American Academy of Dermatology. 67 (4): 748–759. doi:10.1016/j.jaad.2011.07.043. ISSN 1097-6787. PMID 22226429. Check date values in:
|date=(help) - ↑ Deenen, N. J.; et al. (2019-02). "Pitfalls in diagnosing primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma". The British Journal of Dermatology. 180 (2): 411–412. doi:10.1111/bjd.17252. ISSN 1365-2133. PMID 30259963. Check date values in:
|date=(help) - ↑ Willemze, Rein; et al. (2005-05-15). "WHO-EORTC classification for cutaneous lymphomas". Blood. 105 (10): 3768–3785. doi:10.1182/blood-2004-09-3502. ISSN 0006-4971. PMID 15692063.
- ↑ 9.0 9.1 9.2 9.3 9.4 Lee, Katie; et al. (2021-12-09). "Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway". Blood. 138 (23): 2435–2440. doi:10.1182/blood.2021012536. ISSN 1528-0020. PMC 8662071 Check
|pmc=value (help). PMID 34432866 Check|pmid=value (help). - ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Fanoni, Daniele; et al. (2018-12). "Array-based CGH of primary cutaneous CD8+ aggressive EPIDERMO-tropic cytotoxic T-cell lymphoma". Genes, Chromosomes & Cancer. 57 (12): 622–629. doi:10.1002/gcc.22673. ISSN 1098-2264. PMID 30307677. Check date values in:
|date=(help) - ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 Bastidas Torres, Armando N.; et al. (2022-03-01). "Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma". Haematologica. 107 (3): 702–714. doi:10.3324/haematol.2020.274506. ISSN 1592-8721. PMC 8883537 Check
|pmc=value (help). PMID 33792220 Check|pmid=value (help).
EXAMPLE Book
- Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. *Citation of this Page: “Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 07/14/2024, https://ccga.io/index.php/HAEM5:Primary_cutaneous_CD8-positive_aggressive_epidermotropic_cytotoxic_T-cell_lymphoma.